Francois Kerri-Lee A, Msomi Nokukhanya, Govender Kerusha, Gounder Lilishia, Moodley Pravi, Parboosing Raveen, Chetty Indrani, Xaba Lunga, Khan Aabida
Discipline of Virology, Faculty of Health Sciences, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital, Durban, South Africa.
Afr J Lab Med. 2023 Jun 29;12(1):2065. doi: 10.4102/ajlm.v12i1.2065. eCollection 2023.
KwaZulu-Natal ranked second highest among South African provinces for the number of laboratory-confirmed cases during the second wave of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The seroprevalence of SARS-CoV-2 among certain vulnerable groups, such as people living with HIV in KwaZulu-Natal, is unknown.
The study aimed to determine the prevalence of SARS-CoV-2 immunoglobulin G (IgG) in HIV-positive versus HIV-negative patients.
This was a retrospective analysis of residual clinical blood specimens unrelated to coronavirus disease 2019 (COVID-19) submitted for diagnostic testing at Inkosi Albert Luthuli Central Hospital, Durban, from 10 November 2020 to 09 February 2021. Specimens were tested for SARS-CoV-2 immunoglobulin G on the Abbott Architect analyser.
A total of 1977/8829 (22.4%) specimens were positive for SARS-CoV-2 antibodies. Seroprevalence varied between health districts from 16.4% to 37.3%, and was 19% in HIV-positive and 35.3% in HIV-negative specimens. Seroprevalence was higher among female patients (23.6% vs 19.8%; < 0.0001) and increased with increasing age, with a statistically significant difference between the farthest age groups (< 10 years and > 79 years; < 0.0001). The seroprevalence increased from 17% on 10 November 2020 to 43% on 09 February 2021 during the second wave.
Our results highlight that during the second COVID-19 wave in KwaZulu-Natal a large proportion of people living with HIV were still immunologically susceptible. The reduced seropositivity in people with virological failure further emphasises the importance of targeted vaccination and vaccine response monitoring in these individuals.
This study contributes to data on SARS-CoV-2 seroprevalence before and during the second wave in KwaZulu-Natal, South Africa, which has the highest HIV prevalence globally. Reduced seropositivity was found among people living with HIV with virological failure, highlighting the importance of targeted booster vaccination and vaccine response monitoring.
在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行的第二波期间，夸祖鲁-纳塔尔省的实验室确诊病例数在南非各省中排名第二高。SARS-CoV-2在某些弱势群体中的血清流行率尚不清楚，比如夸祖鲁-纳塔尔省的艾滋病毒感染者。
本研究旨在确定艾滋病毒阳性和艾滋病毒阴性患者中SARS-CoV-2免疫球蛋白G（IgG）的流行率。
这是一项对2020年11月10日至2021年2月9日期间提交到德班因科西·阿尔伯特·卢图利中心医院进行诊断检测的与2019冠状病毒病（COVID-19）无关的残留临床血液标本的回顾性分析。在雅培Architect分析仪上对标本进行SARS-CoV-2免疫球蛋白G检测。
总共1977/8829（22.4%）份标本的SARS-CoV-2抗体呈阳性。各健康区的血清流行率在16.4%至37.3%之间，艾滋病毒阳性标本的血清流行率为19%，艾滋病毒阴性标本的血清流行率为35.3%。女性患者的血清流行率更高（23.6%对19.8%；<0.0001），并且随着年龄增长而升高，最年轻年龄组（<10岁）和最年长年龄组（>79岁）之间存在统计学显著差异（<0.0001）。在第二波疫情期间，血清流行率从2020年11月10日的17%上升至2021年2月9日的43%。
我们的结果突出表明，在夸祖鲁-纳塔尔省的第二波COVID-19疫情期间，很大一部分艾滋病毒感染者在免疫方面仍然易感。病毒学失败患者血清阳性率降低进一步强调了对这些个体进行靶向疫苗接种和疫苗反应监测的重要性。
本研究为南非夸祖鲁-纳塔尔省第二波疫情之前和期间SARS-CoV-2血清流行率的数据做出了贡献，该省是全球艾滋病毒流行率最高的地区。在病毒学失败的艾滋病毒感染者中发现血清阳性率降低，突出了靶向加强疫苗接种和疫苗反应监测的重要性。
